National Pension Service Purchases 13,375 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

National Pension Service lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.8% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 1,668,767 shares of the company’s stock after purchasing an additional 13,375 shares during the quarter. National Pension Service’s holdings in Teva Pharmaceutical Industries were worth $27,969,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $43,000. Sound Income Strategies LLC raised its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares during the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $74,000. Brooklyn Investment Group lifted its position in shares of Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after purchasing an additional 4,014 shares in the last quarter. Finally, CWM LLC boosted its holdings in Teva Pharmaceutical Industries by 18.1% during the second quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after purchasing an additional 767 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $25.40 on Friday. The company has a market cap of $29.13 billion, a PE ratio of -158.73, a price-to-earnings-growth ratio of 1.11 and a beta of 0.70. The firm has a 50-day moving average of $20.39 and a 200-day moving average of $18.20. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $26.38. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.10. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period last year, the business posted $0.69 EPS. Teva Pharmaceutical Industries’s revenue was up 3.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

TEVA has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. UBS Group lifted their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $25.86.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the completion of the sale, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.49% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.